Syntezza Bioscience

Syntezza Bioscience Ltd. is the exclusive distributor in Israel of IDT- Integrated DNA Technologies, MGI, Grisp, Trilink and Transomic in Israel. We are also the exclusive distributor in Israel of Macrogen for DNA/Sanger sequencing and BioBasic for genes. In addition, we supply other products, among them custom made peptides from suppliers for whom we are not exclusive distributors. Syntezza aspires to address the needs of the molecular biology community in Israel by providing high quality products for a wide range of applications along with quick delivery time and excellent customer service. Our sales reps in the field are able to keep abreast of the current techniques and changing needs of the customers so that we can continually update and broaden our product lines. Syntezza serves academic and government research facilities as well as corporate customers in the pharmaceutical, agricultural, environmental, biotechnological and medical diagnostic industries. Our product range includes modified and unmodified DNA, RNA, and LNA oligos, genes, RNA silencing and mir products, dual-labeled probes and assays, PCR enzymes, custom-made peptides, NextGen products, and MGC Premier cDNA clones. We offer DNA Sequencing Service and Next Gen Sequencing Services. We also offer subcloning services into a variety of vectors including viral vectors. We provide a number of kits: a DNA extraction kit, a PCR ready-to-use mix which we developed and manufacture as well as the IDT – Surveyor Mutation detection kit.

Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Evogene

Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase probability of success while reducing development time and cost. Evogene established three unique technological engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene’s main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., ag-chemicals by AgPlenus Ltd. and ag-biologicals by Lavie Bio Ltd. For more information, please visit: www.evogene.com

hylabs (Hy Laboratories Ltd)

hylabs is the leading diagnostic company in Israel in the field of microbiology specially in infection diseases. For five decades, it has specialized in the development, production and marketing of services and products for the detection and identification of microorganisms. Today the company leads the field through advanced molecular methods such as RTPCR and NGS (Next Generation Sequencing) or the clinical, industrial, research and innovation markets, alongside the continued production of classical tools for conventional culturing methods. Expertise The products and services offered to the company's customers together with the extensive knowledge and proficiency of our staff are designed to help our customers meet the highest requirements of international and local standards. Our R&D TEAM works closely with leading experts in the field of microbiology and molecular biology, develops and practices the world's most advanced technologies accessible to the market. An internal quality assurance unit oversees all testing performed in laboratories to ensure the accuracy and reliability of the results. The company operates professional customer service and support teams that provide technical assistance both remotely and at the customer's site.

everads therapy ltd

Everads Therapy is an early-stage life sciences company developing the next generation of retinal treatment delivery technologies. With the goal of overcoming significant challenges in current treatment methodologies for retinal and macular diseases, Everads' delivery system offers the promise of improving the efficacy and safety of existing and potential drug therapies. Established in 2017, Everads Therapy operates within the RAD Biomed incubator in Tel Aviv, Israel. Its underlying technologies have been licensed from the Sheba Medical Center at Tel Hashomer.